Research on the efficacy of eicosapentaenoic acid (EPA) on coronary plaque formation in patients undergoing percutaneous coronary intervention.
Not Applicable
- Conditions
- Patients underdoing percutaneous coronary intervention complicated with dyslipidemia.
- Registration Number
- JPRN-UMIN000002059
- Lead Sponsor
- Cardiovascular Medicine. The University of Tokushima Institute of Health Biosciences, Graduate School.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients with a past history of hypersensitivity to high-purity EPA preparations. 2. Patients suffering a stroke within the previous 6 months. 3. Patients with a left vetricular ejection fraction of 40% or less. 4. Patients on dialysis. 5. Patients with bleeding (hemophilia, capilary fragility, gastrointestinal bleeding, urinary tract bleeding, hemoptysis, vitreous hemorrhaging etc.). 6. Patients with peptic ulcers. 7. Patients considered unsuitable for other reasons.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Evaluation of changes in plaque formation before and after medication by integrated backscatter intravascular ultrasound (IB-IVUS).
- Secondary Outcome Measures
Name Time Method 1.Changes in blood inflammation and coagulation markers hs-CRP IL-6 TNF-alpha IP-10 MMP-3 MMP-9 PTX3 Heparin cofactor 2 2.Blood EPA/AA ratio 3.Vascular endothelial function (flow-mediated dilatation; FMD)